Augmented Efficacy of Uttroside B over Sorafenib in a Murine Model of Human Hepatocellular Carcinoma

Mundanattu Swetha, Chenicheri K. Keerthana, Tennyson P. Rayginia, Lekshmi R. Nath, Nair Hariprasad Haritha, Anwar Shabna, Kalishwaralal Kalimuthu, Arun K. Thangarasu, Sreekumar U. Aiswarya, Somaraj Jannet, Sreekumar Pillai, Kuzhuvelil B. Harikumar, Sankar Sundaram, Nikhil Ponnoor Anto, Dee H. Wu, Ravi S. Lankalapalli, Rheal Towner, Noah Isakov, Sathyaseelan S. Deepa, Ruby John Anto

Research output: Contribution to journalArticlepeer-review

Abstract

We previously reported the remarkable potency of uttroside B (Utt-B), saponin-isolated and characterized in our lab from Solanum nigrum Linn, against HCC. Recently, the U.S. FDA approved Utt-B as an ‘orphan drug’ against HCC. The current study validates the superior anti-HCC efficacy of Utt-B over sorafenib, the first-line treatment option against HCC. The therapeutic efficacies of Utt-B vs. sorafenib against HCC were compared in vitro, using various liver cancer cell lines and in vivo, utilizing NOD.CB17-Prkdcscid/J mice bearing human HCC xenografts. Our data indicate that Utt-B holds an augmented anti-HCC efficacy over sorafenib. Our previous report demonstrated the pharmacological safety of Utt-B in Chang Liver, the normal immortalized hepatocytes, and in the acute and chronic toxicity murine models even at elevated Utt-B concentrations. Here, we show that higher concentrations of sorafenib induce severe toxicity, in Chang Liver, as well as in acute and chronic in vivo models, indicating that, apart from the superior therapeutic benefit over sorafenib, Utt-B is a pharmacologically safer molecule, and the drug-induced undesirable effects can, thus, be substantially alleviated in the context of HCC chemotherapy. Clinical studies in HCC patients utilizing Utt-B, is a contiguous key step to promote this drug to the clinic.

Original languageEnglish
Article number636
JournalPharmaceuticals
Volume15
Issue number5
DOIs
StatePublished - 1 May 2022

Keywords

  • apoptosis
  • chemotherapeutic
  • hepatocellular carcinoma
  • sorafenib
  • uttroside B

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Augmented Efficacy of Uttroside B over Sorafenib in a Murine Model of Human Hepatocellular Carcinoma'. Together they form a unique fingerprint.

Cite this